Markers of bone turnover and pain score values in the DNM group at baseline compared with post-DNM administration
| Parameter . | Baseline . | Post DNM . | P . |
|---|---|---|---|
| Bone mineral density, g/cm2 | |||
| L1-L4 | 0.76 (0.60-0.97) | 0.79 (0.62-1.02) | <.001 |
| Femoral neck | 0.60 (0.50-0.86) | 0.65 (0.49-0.97) | .016 |
| Wrist bone | 0.52 (0.20-0.64) | 0.51 (0.20-0.65) | .605 |
| Bone mineral density, T score | |||
| L1-L4 | −2.8 (−4.0 to −0.9) | −2.4 (−4.3 to −0.4) | <.001 |
| Femoral neck | −2.25 (−3.20 to −0.50) | −2.0 (−3.2 to 0.3) | .018 |
| Wrist bone | −3.70 (−11.7 to −1.10) | −3.60 (−11.6 to −0.8) | .832 |
| Bone mineral density, Z score | |||
| L1-L4 | −1.9 (−3.6 to 0.9) | −1.6 (−3.8 to 1.8) | .001 |
| Femoral neck | −1.10 (−2.50 to 0.10) | −0.85 (−2.6 to 0.9) | .004 |
| Wrist bone | −3.10 (−11.1 to 0.70) | −2.95 (−10.9 to 1.0) | .334 |
| Markers of bone resorption | |||
| CTX, ng/mL | 0.12 (0.04-0.50) | 0.02 (0.00-0.38) | <.001 |
| TRACP-5b, U/L | 0.20 (0.07-6.47) | 0.16 (0.04-6.42) | <.001 |
| Markers of bone formation | |||
| bALP, U/L | 11.23 (4.73-55.52) | 9.63 (3.35-43.72) | <.001 |
| OC, ng/mL | 4.49 (0.95-33.65) | 4.98 (0.58-43.73) | .797 |
| Markers of osteoclast activation | |||
| sRANKL, pmol/L | 0.28 (0.07-0.82) | 0.19 (0.05-0.61) | <.001 |
| OPG, pmol/L | 3.9 (1.6-18.8) | 5.33 (2.66-19.76) | <.001 |
| sRANKL/OPG | 0.06 (0.02-0.37) | 0.03 (0.01-0.21) | <.001 |
| Markers of osteoblast inhibition | |||
| Sclerostin, pmol/L | 24.6 (5.2-67.4) | 26.43 (3.54-64.44) | .116 |
| DKK-1, pmol/L | 6.2 (1.5-21.1) | 4.9 (0.01-17.3) | .053 |
| Pain score | |||
| Huskisson’s visual analog scale, cm | 3.4 (0-7.5) | 0.4 (0-2) | <.001 |
| MGM | 2 (0-4) | 0 (0-1) | <.001 |
| Parameter . | Baseline . | Post DNM . | P . |
|---|---|---|---|
| Bone mineral density, g/cm2 | |||
| L1-L4 | 0.76 (0.60-0.97) | 0.79 (0.62-1.02) | <.001 |
| Femoral neck | 0.60 (0.50-0.86) | 0.65 (0.49-0.97) | .016 |
| Wrist bone | 0.52 (0.20-0.64) | 0.51 (0.20-0.65) | .605 |
| Bone mineral density, T score | |||
| L1-L4 | −2.8 (−4.0 to −0.9) | −2.4 (−4.3 to −0.4) | <.001 |
| Femoral neck | −2.25 (−3.20 to −0.50) | −2.0 (−3.2 to 0.3) | .018 |
| Wrist bone | −3.70 (−11.7 to −1.10) | −3.60 (−11.6 to −0.8) | .832 |
| Bone mineral density, Z score | |||
| L1-L4 | −1.9 (−3.6 to 0.9) | −1.6 (−3.8 to 1.8) | .001 |
| Femoral neck | −1.10 (−2.50 to 0.10) | −0.85 (−2.6 to 0.9) | .004 |
| Wrist bone | −3.10 (−11.1 to 0.70) | −2.95 (−10.9 to 1.0) | .334 |
| Markers of bone resorption | |||
| CTX, ng/mL | 0.12 (0.04-0.50) | 0.02 (0.00-0.38) | <.001 |
| TRACP-5b, U/L | 0.20 (0.07-6.47) | 0.16 (0.04-6.42) | <.001 |
| Markers of bone formation | |||
| bALP, U/L | 11.23 (4.73-55.52) | 9.63 (3.35-43.72) | <.001 |
| OC, ng/mL | 4.49 (0.95-33.65) | 4.98 (0.58-43.73) | .797 |
| Markers of osteoclast activation | |||
| sRANKL, pmol/L | 0.28 (0.07-0.82) | 0.19 (0.05-0.61) | <.001 |
| OPG, pmol/L | 3.9 (1.6-18.8) | 5.33 (2.66-19.76) | <.001 |
| sRANKL/OPG | 0.06 (0.02-0.37) | 0.03 (0.01-0.21) | <.001 |
| Markers of osteoblast inhibition | |||
| Sclerostin, pmol/L | 24.6 (5.2-67.4) | 26.43 (3.54-64.44) | .116 |
| DKK-1, pmol/L | 6.2 (1.5-21.1) | 4.9 (0.01-17.3) | .053 |
| Pain score | |||
| Huskisson’s visual analog scale, cm | 3.4 (0-7.5) | 0.4 (0-2) | <.001 |
| MGM | 2 (0-4) | 0 (0-1) | <.001 |
Bold values denote statistical significance. Values are expressed as median (range).